



General Assembly

February Session, 2006

Raised Bill No. 446

LCO No. 2313

02313_____PH_

Referred to Committee on Public Health

Introduced by:
(PH)

**AN ACT MANDATING HEALTH INSURANCE COVERAGE FOR
PHOSPHODIESTERASE TYPE FIVE INHIBITORS FOR MEN
DIAGNOSED WITH PROSTATE CANCER.**

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. Section 38a-492g of the general statutes is repealed and
2 the following is substituted in lieu thereof (*Effective October 1, 2006*):

3 (a) Each individual health insurance policy providing coverage of
4 the type specified in subdivisions (1), (2), (4), (11) and (12) of section
5 38a-469 delivered, issued for delivery, renewed or continued in this
6 state on or after January 1, 2000, shall provide coverage for laboratory
7 and diagnostic tests, including, but not limited to, prostate specific
8 antigen (PSA) tests, to screen for prostate cancer for men who are
9 symptomatic, whose biological father or brother has been diagnosed
10 with prostate cancer, and for all men fifty years of age or older.

11 (b) Each individual health insurance policy providing coverage of
12 the type specified in subdivisions (1), (2), (4), (11) and (12) of section
13 38a-469 delivered, issued for delivery, amended, renewed or continued
14 in this state on or after October 1, 2006, that provides coverage for

15 outpatient prescription drugs approved by the federal Food and Drug
16 Administration shall not exclude coverage for up to twenty tablets per
17 month of phosphodiesterase type five inhibitors, for a period of two
18 years or less, for any male who has been diagnosed with, and received
19 treatment for, prostate cancer.

20 Sec. 2. Section 38a-518g of the general statutes is repealed and the
21 following is substituted in lieu thereof (*Effective October 1, 2006*):

22 (a) Each group health insurance policy providing coverage of the
23 type specified in subdivisions (1), (2), (4), (11) and (12) of section 38a-
24 469 delivered, issued for delivery, renewed or continued in this state
25 on or after January 1, 2000, shall provide coverage for laboratory and
26 diagnostic tests, including, but not limited to, prostate specific antigen
27 (PSA) tests, to screen for prostate cancer for men who are
28 symptomatic, whose biological father or brother has been diagnosed
29 with prostate cancer, and for all men fifty years of age or older.

30 (b) Each group health insurance policy providing coverage of the
31 type specified in subdivisions (1), (2), (4), (11) and (12) of section 38a-
32 469 delivered, issued for delivery, amended, renewed or continued in
33 this state on or after October 1, 2006, that provides coverage for
34 outpatient prescription drugs approved by the federal Food and Drug
35 Administration shall not exclude coverage for up to twenty tablets per
36 month of phosphodiesterase type five inhibitors, for a period of two
37 years or less, for any male who has been diagnosed with, and received
38 treatment for, prostate cancer.

This act shall take effect as follows and shall amend the following sections:		
Section 1	<i>October 1, 2006</i>	38a-492g
Sec. 2	<i>October 1, 2006</i>	38a-518g

Statement of Purpose:

To require health insurance companies to provide coverage for prescription drugs used to treat erectile dysfunction following treatment for prostate cancer.

[Proposed deletions are enclosed in brackets. Proposed additions are indicated by underline, except that when the entire text of a bill or resolution or a section of a bill or resolution is new, it is not underlined.]